Diagnosis of prostate cancer is primarily based on PSA testing, digital rectal examination (DRE) and imaging to select men for prostate biopsy. Moderately elevated PSA concentrations (3-10 ng/ml) have limited specificity for detection, indicating the need for more accurate biomarkers. PSA-density (PSA-D), derived from PSA level divided by prostate volume, can add value in predicting clinically significant disease.1 Several blood…
Local and locoregional prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up†
Annals of Oncology | | J. Walz, G. Attard, A. Bjartell, P. Blanchard, E. Castro, E. Compérat, L. Emmett, S. Fanti, V. Fonteyne, S. Foulon, S. Gillessen, G. Gravis, N.D. James, D.E. Oprea-Lager, P. Ost, A. Padhani, C. Parker, R.M. Renard-Penna, M.A. Rubin, F. Saad, C. Sweeney, D. Tilki, B. Tombal, A.C. Tree, T. Zilli, K. Fizazi, ESMO Guidelines Committee
Topics: prostate-cancer, blood-cancer, targeted-therapy, research